Author + information
- Received January 3, 2012
- Revision received March 14, 2012
- Accepted March 16, 2012
- Published online May 1, 2012.
- Stefan Toggweiler, MD⁎,
- David A. Wood, MD⁎,
- Josep Rodés-Cabau, MD†,
- Samir Kapadia, MD‡,
- Alexander B. Willson, MBBS, MPH⁎,
- Jian Ye, MD⁎,
- Anson Cheung, MD⁎,
- Jonathon Leipsic, MD⁎,
- Ronald K. Binder, MD⁎,
- Ronen Gurvitch, MBBS⁎,
- Melanie Freeman, MBBS⁎,
- Christopher R. Thompson, MD⁎,
- Lars G. Svensson, MD‡,
- Eric Dumont, MD†,
- E. Murat Tuzcu, MD‡ and
- John G. Webb, MD⁎,⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. John G. Webb, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
Objectives This study sought to evaluate outcomes after implantation of a second transcatheter heart valve (THV-in-THV) for acute THV failure.
Background Aortic regurgitation after transcatheter aortic valve replacement (TAVR) may be valvular due to prosthetic leaflet dysfunction or paravalvular due to poor annular sealing.
Methods Patients undergoing aortic balloon-expandable TAVR at 3 centers were prospectively evaluated at baseline, intraprocedurally, at hospital discharge, and annually.
Results Of 760 patients undergoing TAVR, 21 (2.8%) received a THV-in-THV implant due to acute, severe regurgitation. Aortic regurgitation was paravalvular in 18 patients and transvalvular in the remaining 3 patients. THV-in-THV implantation was technically successful in 19 patients (90%) and unsuccessful in 2 patients (10%), who subsequently underwent open heart surgery. Mortality at 30 days and 1 year was 14.3% and 24%, respectively. After successful THV-in-THV, mean aortic valve gradient fell from 37 ± 12 mm Hg to 13 ± 5 mm Hg (p < 0.01); aortic valve area increased from 0.64 ± 0.14 cm2 to 1.55 ± 0.27 cm2 (p < 0.01); and paravalvular aortic regurgitation was none in 4 patients, mild in 13 patients, and moderate in 2 patients. At 1-year follow-up, 1 patient had moderate and the others had mild or no paravalvular leaks. The mean transvalvular gradient was 15 ± 4 mm Hg, which was higher than in patients undergoing conventional TAVR (11 ± 4 mm Hg, p = 0.02).
Conclusions THV-in-THV implantation is feasible and results in satisfactory short- and mid-term outcomes.
- aortic stenosis
- aortic valve regurgitation
- transcatheter aortic valve implantation
- transcatheter aortic valve replacement
Drs. Toggweiler and Binder are supported by a grant of the Swiss National Foundation. Drs. Wood, Rodés-Cabau, Ye, Cheung, Leipsic, and Webb are consultants to Edwards Lifesciences. Drs. Wood and Rodés-Cabau are also consultants for St. Jude Medical. Dr. Leipsic is also on the Speaker's Bureau and Advisory Board for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received January 3, 2012.
- Revision received March 14, 2012.
- Accepted March 16, 2012.
- 2012 American College of Cardiology Foundation